Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, has announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on December 8, 2022, from 8:00-8:30am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inozyme Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, has announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on December 8, 2022, from 8:00-8:30am ET. The event will showcase insights into the company’s work on novel therapeutics, particularly INZ701, a potential first-in-class enzyme therapy for pathologic mineralization and intimal proliferation.
A replay will be available on their website after the event.
Details
News Market Reaction – INZY
The recorded move for INZY in the trading session of this news was -2.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET.
A replay of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the event.
About Inozyme Pharma
Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ701, a potential first-in-class enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
For more information, please visit www.inozyme.com and follow us on LinkedIn, Twitter, and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com
Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.